Home › Peripheral Arterial Disease › NCT06300450

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* All patients ≥ 18 years old
* Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology
* Medical history entry, visit diagnosis, or problem list entry of PAD
* Not prescribed LDL-C-lowering therapy

Exclusion Criteria:

* Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded

About the study

This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.

What is being tested

• Computer Alert (behavioral)

Sponsor: Brigham and Women's Hospital · Participants: 400 · Started: Mar 1, 2023

Contact the study team

• Gregory Piazza · Phone: 6177326984
• Candrika D Kharaini · Phone: 6177326984

Official record on ClinicalTrials.gov — NCT06300450

Locations in the U.S.

Conditions

• Peripheral Arterial Disease
• Dyslipidemias

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.